{"disease":{"id":"hereditary-factor-ix-deficiency-disease","name":"Hereditary factor IX deficiency disease","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":6,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"eftrenonacog-alfa","indication_name":"Hereditary factor IX deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alprolix","generic_name":"EFTRENONACOG ALFA","company_name":"Swedish Orphan Biovitrum AB","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":"300","mechanism":""},{"drug_id":"eptacog-alfa-activated","indication_name":"Hereditary factor IX deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Eptacog Alfa","generic_name":"EPTACOG ALFA (ACTIVATED)","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"nonacog-alfa","indication_name":"Hereditary factor IX deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Recombinant Coagulation Factor Ix","generic_name":"nonacog alfa","company_name":"Pfizer Ltd","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":""},{"drug_id":"albutrepenonacog-alfa","indication_name":"Hereditary factor IX deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Idelvion","generic_name":"ALBUTREPENONACOG ALFA","company_name":"CSL Behring GmbH","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":""},{"drug_id":"nonacog-alfa-genetical-recombination","indication_name":"Hereditary factor IX deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nonacog Alfa (Genetical Recombination)","generic_name":"nonacog-alfa-genetical-recombination","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"Patients with hemophilia B (congenital blood coagulation factor IX deficiency) who are administered ","quality_score":null,"revenue":null,"mechanism":"Patients with hemophilia B (congenital blood coagulation factor IX deficiency) who are administered "},{"drug_id":"alprolix","indication_name":"Hereditary factor IX deficiency disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Alprolix","company_name":"Swedish Orphan Biovitrum","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}